#ACTRIMS2019 – Jeffrey Cohen, MD, is New President of ACTRIMS
Jeffrey Cohen, MD, director of the experimental therapeutics program at the Mellen Center for Multiple Sclerosis Treatment and Research at…
Articles by Bionews Staff
#ECTRIMS2018 – MS PATHS Just Starting to See Potential, Aims for Remission as Treatment Goal, Biogen Exec Says
MS PATHS, a way of capturing data on disease progression and treatment response in thousands of multiple sclerosis (MS)…
#ECTRIMS2018 – Post-hoc Analyses Support Safety and Efficacy of Mavenclad, Merck KGaA Says
Substantial data supporting both the effectiveness and safety of Mavenclad (cladribine tablets) is before the U.S. Food and…
#ECTRIMS2018 — As Siponimod Awaits FDA Decision, Mouse Work Helps in Understanding Benefits Seen in SPMS
Mouse studies of siponimod — a potential progressive multiple sclerosis (MS) treatment that’s up for approval in the U.S. and…
#ECTRIMS2018 – From Sun to Salt: Growing Role of Environment in MS
A person’s genes influence the development of multiple sclerosis (MS), but so does the environment — both that in which…
#ECTRIMS2018 — Data from 2 EU Trials Shows Effectiveness of Cannabidiol Spray in Treating Spasticity
Data from two European trials — a real-life study in Italy, and a long-term Czech trial looking at impact on…
#ECTRIMS2018 – Emerging MS Treatments, from Cannabinoids to Diet, Among Highlights at Conference
Thousands of scientists, doctors, pharmaceutical company executives and others — representing about 100 countries — will meet for three days…
#MSParis2017 – Advances in Progressive and Pediatric MS Top ECTRIMS Highlights, NMSS Says
A giant leap in research and interest in progressive multiple sclerosis — from a few people pushing for such work…
#MSParis2017 – Ocrevus Trial Data May Lead to Key Biomarkers of Chronic Inflammation, Genentech Says
Potential new ways of capturing disease progression in multiple sclerosis (MS) patients — including those with chronic as opposed to…
#MSParis2017 – Lemtrada Shows Good Safety and Lasting Efficacy Over 7 Years, Doctor Says in Interview
Lemtrada (alemtuzumab) remains a “game-changer” of a treatment for relapsing multiple sclerosis (MS), with benefits continuing and no new side…
#MSParis2017 – Potential Progressive MS Treatment on Move in US and Europe, MedDay CEO Says
This is a special edition of Multiple Sclerosis News Today's daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway in Paris, France. The MS News today team in on-site at the conference, providing exclusive coverage of the presentations and speakers.
MS Australia Puts Out an Owner’s Manual for ‘MS Bike’ and Anyone Willing to Take It for a Spin
A bicycle specially designed to mimic the symptoms of multiple sclerosis (MS) now has its own owner’s manual, and the…
#CMSC16 – An Interview with Dr. Fred Lublin of the Center for Multiple Sclerosis at Mount Sinai
Dr. Fred Lublin, a neuroimmunologist with a specialty in experimental therapies, will open this year’s annual meeting of the…
#CMSC16 – An Interview with June Halper, the Consortium’s CEO and an MS Nurse Practitioner
When the 2016 annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) opens June 1, marking the organization’s…
FDA Grants ‘Breakthrough Therapy’ Designation to Genentech’s Ocrelizumab for PPMS
Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment…
Bike With Multiple Sclerosis Symptoms Debuts for 2016 Australia Fundraising Race
One of the teams participating in the 10th anniversary of the MS Melbourne Cycle, an annual biking challenge to raise…
Coral Gables, FL MS Exchange Event This Saturday To Explore Relapsing MS Management
An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area…
Mike Nace, Editor-in-Chief of Multiple Sclerosis News Today, Reviews Day 2-3 at #ECTRIMS2015
https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3 Read the articles mentioned in the podcast: #ECTRIMS2015 – Another Attendee Record #ECTRIMS2015 – “Vitamin D plays important…
FDA Taps Online Patient Database To Gain Access To Patient-Reported MS Health Data
In an effort to access firsthand patient data as a means of improving healthcare and drug safety, the Food and…
Spasticity Drug to be Tested on Multiple Sclerosis Patients in Early 2015
Concert Pharmaceuticals, Inc. will announce their latest results from the Phase 1 data of CTP-354, a drug developed to…
Higher Body Temperature in RRMS Patients Could Cause Increased Fatigue
Researchers have recently discovered that the fatigue that patients with multiple sclerosis (MS) experience is not the same kind of fatigue…
JCV Virus May Be Missed in Patients Who Take Popular MS Drug, According To Study
Multiple sclerosis (MS) patients who are prescribed Tysabri have an increased risk to develop the rare, often fatal infection of the brain…
MS Views & News Awards Questcor With “Recognition of Appreciation” Award Multiple Sclerosis Advocacy
Questcor Pharmaceuticals, Inc. is a drug development company with a viable Multiple Sclerosis drug called H.P. Acthar® Gel, which…
New Multiple Sclerosis Drug Target of U.S. and Japanese Researchers
The National Center of Neurology and Psychiatry, based in Japan, announced that they will initiate a 3-month clinical trial on 9 patients…
Benefits of Cognitive Reserve in Multiple Sclerosis May Also Benefit TBI Patients
Researchers from the Kessler Foundation have found that higher educational achievement reduces the negative impact of traumatic brain injury (TBI) on cognitive status.